Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Jan G. P. Tijssen"'
Autor:
Niekbachsh Mohammadnia, Jan Los, Tjerk S. J. Opstal, Aernoud T. L. Fiolet, John W. Eikelboom, Arend Mosterd, Stefan M. Nidorf, Charley A. Budgeon, Jan G. P. Tijssen, Peter L. Thompson, Cees J. Tack, Suat Simsek, Willem A. Bax, Jan H. Cornel, Saloua El Messaoudi
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 10 (2023)
IntroductionDespite optimal treatment, patients with chronic coronary artery disease (CAD) and diabetes mellitus (DM) are at high risk of cardiovascular events, emphasizing the need for new treatment options. The Low-Dose Colchicine 2 (LoDoCo2) trial
Externí odkaz:
https://doaj.org/article/22bccdd36673494589e80219438b8e8b
Autor:
Arno M. Wiersema, Liliane C. Roosendaal, Mark J. W. Koelemaij, Jan G. P. Tijssen, Susan van Dieren, Jan D. Blankensteijn, E. Sebastian Debus, Saskia Middeldorp, Jan M. M. Heyligers, Ymke S. Fokma, Michel M. P. J. Reijnen, Vincent Jongkind
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-16 (2021)
Abstract Background Heparin is used worldwide for 70 years during all non-cardiac arterial procedures (NCAP) to reduce thrombo-embolic complications (TEC). But heparin also increases blood loss causing possible harm for the patient. Heparin has an un
Externí odkaz:
https://doaj.org/article/960975c75da441748afb415e14ef7f44
Autor:
Dominique V. M. Verhaert, Dominik Linz, Sevasti Maria Chaldoupi, Sjoerd W. Westra, Dennis W. den Uijl, Suzanne Philippens, Mijke Kerperien, Zarina Habibi, Bianca Vorstermans, Rachel M. A. ter Bekke, Rypko J. Beukema, Reinder Evertz, Martin E. W. Hemels, Justin G. L. M. Luermans, Randolph Manusama, Theo A. R. Lankveld, Claudia A. J. van der Heijden, Elham Bidar, Ben J. M. Hermans, Stef Zeemering, Geertruida P. Bijvoet, Jesse Habets, Robert J. Holtackers, Casper Mihl, Robin Nijveldt, Vanessa P. M. van Empel, Christian Knackstedt, Sami O. Simons, Wolfgang F. F. A. Buhre, Jan G. P. Tijssen, Aaron Isaacs, Harry J. G. M. Crijns, Bart Maesen, Kevin Vernooy, Ulrich Schotten
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2022)
IntroductionContinuous progress in atrial fibrillation (AF) ablation techniques has led to an increasing number of procedures with improved outcome. However, about 30–50% of patients still experience recurrences within 1 year after their ablation.
Externí odkaz:
https://doaj.org/article/a4857046cedb4b3ba1db6f6b80b721a5
Autor:
Reinoud E Knops, Shari Pepplinkhuizen, Peter Paul H M Delnoy, Lucas V A Boersma, Juergen Kuschyk, Mikhael F El-Chami, Hendrik Bonnemeier, Elijah R Behr, Tom F Brouwer, Stefan Kaab, Suneet Mittal, Anne-Floor B E Quast, Willeke van der Stuijt, Lonneke Smeding, Jolien A de Veld, Jan G P Tijssen, Nick R Bijsterveld, Sergio Richter, Marc A Brouwer, Joris R de Groot, Kirsten M Kooiman, Pier D Lambiase, Petr Neuzil, Kevin Vernooy, Marco Alings, Timothy R Betts, Frank A L E Bracke, Martin C Burke, Jonas S S G de Jong, David J Wright, Ward P J Jansen, Zachary I Whinnett, Peter Nordbeck, Michael Knaut, Berit T Philbert, Jurren M van Opstal, Alexandru B Chicos, Cornelis P Allaart, Alida E Borger van der Burg, Jose M Dizon, Marc A Miller, Dmitry Nemirovsky, Ralf Surber, Gaurav A Upadhyay, Raul Weiss, Anouk de Weger, Arthur A M Wilde, Louise R A Olde Nordkamp
Publikováno v:
European heart journal, 43(47), 4872-4883. Oxford University Press
European Heart Journal, 43, 4872-4883
European Heart Journal, 43(47), 4872-4883. Oxford University Press
Knops, R E, Pepplinkhuizen, S, Delnoy, P P H M, Boersma, L V A, Kuschyk, J, El-Chami, M F, Bonnemeier, H, Behr, E R, Brouwer, T F, Kaab, S, Mittal, S, Quast, A-F B E, van der Stuijt, W, Smeding, L, de Veld, J A, Tijssen, J G P, Bijsterveld, N R, Richter, S, Brouwer, M A, de Groot, J R, Kooiman, K M, Lambiase, P D, Neuzil, P, Vernooy, K, Alings, M, Betts, T R, Bracke, F A L E, Burke, M C, de Jong, J S S G, Wright, D J, Jansen, W P J, Whinnett, Z I, Nordbeck, P, Knaut, M, Philbert, B T, van Opstal, J M, Chicos, A B, Allaart, C P, Borger van der Burg, A E, Dizon, J M, Miller, M A, Nemirovsky, D, Surber, R, Upadhyay, G A, Weiss, R, de Weger, A, Wilde, A A M & Olde Nordkamp, L R A 2022, ' Device-related complications in subcutaneous versus transvenous ICD : a secondary analysis of the PRAETORIAN trial ', European Heart Journal, vol. 43, no. 47, pp. 4872-4883 . https://doi.org/10.1093/eurheartj/ehac496, https://doi.org/10.1093/eurheartj/ehac496
European Heart Journal, 43, 47, pp. 4872-4883
European Heart Journal, 43, 4872-4883
European Heart Journal, 43(47), 4872-4883. Oxford University Press
Knops, R E, Pepplinkhuizen, S, Delnoy, P P H M, Boersma, L V A, Kuschyk, J, El-Chami, M F, Bonnemeier, H, Behr, E R, Brouwer, T F, Kaab, S, Mittal, S, Quast, A-F B E, van der Stuijt, W, Smeding, L, de Veld, J A, Tijssen, J G P, Bijsterveld, N R, Richter, S, Brouwer, M A, de Groot, J R, Kooiman, K M, Lambiase, P D, Neuzil, P, Vernooy, K, Alings, M, Betts, T R, Bracke, F A L E, Burke, M C, de Jong, J S S G, Wright, D J, Jansen, W P J, Whinnett, Z I, Nordbeck, P, Knaut, M, Philbert, B T, van Opstal, J M, Chicos, A B, Allaart, C P, Borger van der Burg, A E, Dizon, J M, Miller, M A, Nemirovsky, D, Surber, R, Upadhyay, G A, Weiss, R, de Weger, A, Wilde, A A M & Olde Nordkamp, L R A 2022, ' Device-related complications in subcutaneous versus transvenous ICD : a secondary analysis of the PRAETORIAN trial ', European Heart Journal, vol. 43, no. 47, pp. 4872-4883 . https://doi.org/10.1093/eurheartj/ehac496, https://doi.org/10.1093/eurheartj/ehac496
European Heart Journal, 43, 47, pp. 4872-4883
Background The subcutaneous implantable cardioverter-defibrillator (S-ICD) is developed to overcome lead-related complications and systemic infections, inherent to transvenous ICD (TV-ICD) therapy. The PRAETORIAN trial demonstrated that the S-ICD is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e757a40a17c07ec6eba44a3463f1765a
https://pure.amc.nl/en/publications/devicerelated-complications-in-subcutaneous-versus-transvenous-icd(6df2d41e-5aad-4930-8f10-615ecb7136ac).html
https://pure.amc.nl/en/publications/devicerelated-complications-in-subcutaneous-versus-transvenous-icd(6df2d41e-5aad-4930-8f10-615ecb7136ac).html
Autor:
Amber van Broekhoven, Niekbachsh Mohammadnia, Max J. M. Silvis, Jonathan Los, Aernoud T. L. Fiolet, Tjerk S. J. Opstal, Arend Mosterd, John W. Eikelboom, Stefan M. Nidorf, Charley A. Budgeon, Elizabeth Byrnes, Willem A. Bax, Jan G. P. Tijssen, Dominique P. V. de Kleijn, Peter L. Thompson, Saloua El Messaoudi, Jan H. Cornel
Publikováno v:
Clinical drug investigation, 42(11), 977-985. Adis International Ltd
Clinical Drug Investigation, 42, 977-985
Clinical Drug Investigation, 42, 11, pp. 977-985
Clinical Drug Investigation, 42, 977-985
Clinical Drug Investigation, 42, 11, pp. 977-985
Contains fulltext : 288089.pdf (Publisher’s version ) (Open Access) BACKGROUND AND OBJECTIVE: The Low-Dose Colchicine-2 (LoDoCo2) trial showed that 2-4 years exposure to colchicine 0.5 mg once daily reduced the risk of cardiovascular events in pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a7e75f557f8750b00f611a1192bac17
https://research.vumc.nl/en/publications/94450c2a-4c60-47b0-a72e-c9b9f640b416
https://research.vumc.nl/en/publications/94450c2a-4c60-47b0-a72e-c9b9f640b416
Autor:
Amber, van Broekhoven, Niekbachsh, Mohammadnia, Max J M, Silvis, Jonathan, Los, Aernoud T L, Fiolet, Tjerk S J, Opstal, Arend, Mosterd, John W, Eikelboom, Stefan M, Nidorf, Charley A, Budgeon, Elizabeth, Byrnes, Willem A, Bax, Jan G P, Tijssen, Dominique P V, de Kleijn, Peter L, Thompson, Saloua, El Messaoudi, Jan H, Cornel
Publikováno v:
Clinical drug investigation. 42(11)
The Low-Dose Colchicine-2 (LoDoCo2) trial showed that 2-4 years exposure to colchicine 0.5 mg once daily reduced the risk of cardiovascular events in patients with chronic coronary artery disease. The potential effect of years-long exposure to colchi
Autor:
Stefan M, Nidorf, Aernoud T L, Fiolet, Arend, Mosterd, John W, Eikelboom, Astrid, Schut, Tjerk S J, Opstal, Salem H K, The, Xiao-Fang, Xu, Mark A, Ireland, Timo, Lenderink, Donald, Latchem, Pieter, Hoogslag, Anastazia, Jerzewski, Peter, Nierop, Alan, Whelan, Randall, Hendriks, Henk, Swart, Jeroen, Schaap, Aaf F M, Kuijper, Maarten W J, van Hessen, Pradyot, Saklani, Isabel, Tan, Angus G, Thompson, Allison, Morton, Chris, Judkins, Willem A, Bax, Maurits, Dirksen, Marco, Alings, Graeme J, Hankey, Charley A, Budgeon, Jan G P, Tijssen, Jan H, Cornel, Peter L, Thompson, Karen, Youl
Publikováno v:
LoDoCo2 Trial Investigators 2020, ' Colchicine in patients with chronic coronary disease ', New England Journal of Medicine, vol. 383, no. 19, pp. 1838-1847 . https://doi.org/10.1056/NEJMoa2021372
The New England Journal of Medicine, 383, 1838-1847
The New England Journal of Medicine, 383, 19, pp. 1838-1847
New England journal of medicine, 383(19), 1838-1847. Massachussetts Medical Society
New England Journal of Medicine, 383(19), 1838-1847. Massachussetts Medical Society
The New England Journal of Medicine, 383, 1838-1847
The New England Journal of Medicine, 383, 19, pp. 1838-1847
New England journal of medicine, 383(19), 1838-1847. Massachussetts Medical Society
New England Journal of Medicine, 383(19), 1838-1847. Massachussetts Medical Society
Evidence from a recent trial has shown that the antiinflammatory effects of colchicine reduce the risk of cardiovascular events in patients with recent myocardial infarction, but evidence of such a risk reduction in patients with chronic coronary dis
Autor:
Thomas P W, van den Boogert, Jeroen, Vendrik, Jetske L B, Gunster, Martijn S, van Mourik, Bimmer E P M, Claessen, Floortje, van Kesteren, Karel T, Koch, Joanna J, Wykrzykowska, M Marije, Vis, Toon A, Winkelman, Antoine H G, Driessen, Marcel A M, Beijk, Robbert J, de Winter, Jan G P, Tijssen, Nils R, Planken, Jan, Baan, José P, Henriques
Publikováno v:
The Journal of invasive cardiology. 33(10)
To analyze the effect of percutaneous coronary intervention (PCI) before transcatheter aortic valve replacement (TAVR) on all-cause and cardiovascular mortality after TAVR, differentiating between significant proximal lesions and the non-proximal (re
Autor:
Ruben R De With, Michiel Rienstra, Marcelle D Smit, Bob Weijs, Victor W Zwartkruis, Anne H Hobbelt, Marco Alings, Jan G P Tijssen, Johan Brügemann, Bastiaan Geelhoed, Hans L Hillege, Raymond Tukkie, Martin E Hemels, Robert G Tieleman, Adelita V Ranchor, Dirk J Van Veldhuisen, Harry J G M Crijns, Isabelle C Van Gelder
Publikováno v:
Europace, 21(4), 563-571. Oxford University Press
Europace, 21, 4, pp. 563-571
EP Europace, 21(4), 563-571. Oxford University Press
Europace, 21, 563-571
Europace, 21, 4, pp. 563-571
EP Europace, 21(4), 563-571. Oxford University Press
Europace, 21, 563-571
AIMS: Atrial fibrillation (AF) reduces quality of life (QoL). We aim to evaluate effects of targeted therapy of underlying conditions on QoL in patients with AF and heart failure (HF). METHODS AND RESULTS: The Routine versus Aggressive risk factor dr
Autor:
Pier Woudstra, Peter Damman, Wichert J Kuijt, Wouter J Kikkert, Maik J Grundeken, Peter M van Brussel, An K Stroobants, Jan P van Straalen, Johan C Fischer, Karel T Koch, José P S Henriques, Jan J Piek, Jan G P Tijssen, Robbert J de Winter
Publikováno v:
PLoS ONE, Vol 9, Iss 5, p e96251 (2014)
BACKGROUND: Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity is a biomarker predicting cardiovascular diseases in a real-world. However, the prognostic value in patients undergoing primary percutaneous coronary intervention (pPCI) for ST-se
Externí odkaz:
https://doaj.org/article/24a1b548da354adf84337f2e9715c24f